AQP1 (Aquaporin-1) variants and mutations
AQP1 (also known as Aquaporin-1) is a human protein-coding gene encoding an aquaporin-1 protein. It enables rapid water movement across cell membranes and also conducts gases and, under some conditions, ions in vascular, renal, and other tissues. Rare loss-of-function variants produce the Colton-null blood-group phenotype and can impair urinary concentrating ability. This analysis covers 634 AQP1 variants and mutations. Of these, 97% have computational variant effect predictions. Disease context includes osteoporosis, nephrolithiasis, and bone disorder. Example AQP1 variants include M1T, M1I, and M1V.
Variant analysis overview
- Gene: AQP1
- Protein: Aquaporin-1
- UniProt accession: P29972
- Organism: Homo sapiens
- Variants analyzed: 634
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 320 unspecified-consequence records; 110 synonymous variants; 175 missense variants; 19 frameshift variants; 3 stop-gained variants; 5 in-frame deletions; 2 splice-region variants
- Prediction scores: 615 variants have prediction scores (97% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: osteoporosis, nephrolithiasis, bone disorder, bone fracture, gout, bladder calculus, preeclampsia, urolithiasis, hemolysis, ocular hypotension, heritable pulmonary arterial hypertension, radius fracture.
Protein structure and variant hotspots
- Protein features: 6 transmembrane segments; 5 post-translational modification sites.
- Structural context: 286 variants have structural context.
- PTM context: 9 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable AQP1 variants
Examples include M1T, M1I, M1V, A2T, A2A, S3R, S3G, S3S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), gnomAD 7-30921599-T-C, CADD 7.95, SIFT 0.00
- M1I (p.Met1Ile), gnomAD 7-30921600-G-T, CADD 4.98, SIFT 0.06
- M1V (p.Met1Val), rs994263324, gnomAD 7-30921704-A-G, CADD 3.61, SIFT 0.15
- A2T (p.Ala2Thr), ESP rs144950903, ExAC rs144950903, TOPMed rs144950903, gnomAD rs144950903, REVEL 0.34, MetaLR 0.67
- A2A (p.Ala2Ala), rs1791174003, gnomAD 7-30911915-C-T, CADD 13.80
- S3R (p.Ser3Arg), 1000Genomes rs574768358, ExAC rs574768358, TOPMed rs574768358, gnomAD rs574768358, REVEL 0.17, MetaLR 0.32
- S3G (p.Ser3Gly), gnomAD 7-30911916-A-G, REVEL 0.16, MetaLR 0.40
- S3S (p.Ser3Ser), rs574768358, gnomAD 7-30911918-C-T, CADD 8.88
- S3L (p.Ser3Leu), rs867023718, gnomAD 7-30921593-C-T, CADD 0.57, SIFT 0.06
- S3P (p.Ser3Pro), gnomAD 7-30921638-T-C, CADD 3.66, SIFT 0.00
- S3C (p.Ser3Cys), gnomAD 7-30921639-C-G, CADD 0.31, SIFT 0.00
- E4K (p.Glu4Lys), rs1401166675, NCI-TCGA Cosmic COSV6126, gnomAD rs1401166675, REVEL 0.89, MetaLR 0.92, Variant assessed as somatic; moderate impact.
- E4Q (p.Glu4Gln), gnomAD rs1401166675, REVEL 0.88, MetaLR 0.90
- E4R (p.Glu4Arg), rs1464116956, gnomAD 7-30911917-G-GC, CADD 29.40
- E4* (p.Glu4Ter), gnomAD 7-30911919-G-T, CADD 38.00
- E4G (p.Glu4Gly), gnomAD 7-30911920-A-G, REVEL 0.90, MetaLR 0.90
- E4E (p.Glu4Glu), rs374468237, gnomAD 7-30911921-G-A, CADD 11.20
- E4D (p.Glu4Asp), gnomAD 7-30921631-A-T, CADD 7.36, SIFT 0.00
- F5L (p.Phe5Leu), ExAC rs767122207, REVEL 0.16, MetaLR 0.15
- F5V (p.Phe5Val), NCI-TCGA Cosmic COSV1003, ExAC rs756931426, TOPMed rs756931426, gnomAD rs756931426, REVEL 0.28, MetaLR 0.34, Variant assessed as somatic; moderate impact.
- F5I (p.Phe5Ile), gnomAD 7-30911922-T-A, REVEL 0.17, MetaLR 0.34
- F5C (p.Phe5Cys), gnomAD 7-30921621-T-G, CADD 5.58, SIFT 1.00
- F5S (p.Phe5Ser), rs1791501783, gnomAD 7-30921621-T-C, CADD 5.93, SIFT 0.00
- K6R (p.Lys6Arg), ExAC rs754247100, TOPMed rs754247100, gnomAD rs754247100, REVEL 0.20, MetaLR 0.36
- K6E (p.Lys6Glu), gnomAD 7-30911925-A-G, REVEL 0.58, MetaLR 0.49
- K6N (p.Lys6Asn), gnomAD 7-30911927-G-C, REVEL 0.47, MetaLR 0.52
- K7N (p.Lys7Asn), NCI-TCGA Cosmic COSV6126, MetaLR 0.46, MetaSVM -0.15, Variant assessed as somatic; moderate impact.
- K7R (p.Lys7Arg), rs755354795, ClinGen CA4208025, ClinVar RCV004276080, ExAC rs755354795, REVEL 0.31, MetaLR 0.44, Uncertain significance, not specified
- K8E (p.Lys8Glu), gnomAD rs1269219164, REVEL 0.70, MetaLR 0.61
- K8del (p.Lys8del), rs1391602963, gnomAD 7-30911924-CAAG-C, CADD 19.60
- L9F (p.Leu9Phe), gnomAD 7-30911934-C-T, REVEL 0.26, MetaLR 0.38
- L9L (p.Leu9Leu), rs779206938, gnomAD 7-30911936-C-G, CADD 9.93
- F10C (p.Phe10Cys), rs2534992209, ClinGen CA367147388, ClinVar RCV004420007, Uncertain significance, not specified
- F10F (p.Phe10Phe), rs1004522432, gnomAD 7-30911939-C-T, CADD 12.30
- W11C (p.Trp11Cys), NCI-TCGA Cosmic COSV6126, MetaLR 0.92, MetaSVM 1.05, Variant assessed as somatic; moderate impact.
- W11R (p.Trp11Arg), gnomAD 7-30911940-T-C, REVEL 0.91, MetaLR 0.88
- W11* (p.Trp11Ter), rs1311863823, gnomAD 7-30921605-G-A, CADD 0.17
- R12K (p.Arg12Lys), TOPMed rs1016862979
- R12S (p.Arg12Ser), gnomAD rs1219898649, REVEL 0.91, MetaLR 0.78
- R12C (p.Arg12Cys), rs776497596, gnomAD 7-30921716-C-T, CADD 0.04, SIFT 0.73
- R12L (p.Arg12Leu), rs187798109, gnomAD 7-30921717-G-T, CADD 0.16, SIFT 0.10
- R12H (p.Arg12His), rs187798109, gnomAD 7-30921717-G-A, CADD 0.20, SIFT 0.03
- A13V (p.Ala13Val), TOPMed rs1791175000, gnomAD rs1791175000, REVEL 0.74, MetaLR 0.81
- A13A (p.Ala13Ala), rs748606187, gnomAD 7-30911948-A-G, CADD 4.47
- A13P (p.Ala13Pro), gnomAD 7-30921644-G-C, CADD 3.63, SIFT 0.00
- V14V (p.Val14Val), rs1333547669, gnomAD 7-30911951-G-T, CADD 10.30
- V14L (p.Val14Leu), rs537605954, gnomAD 7-30921635-G-C, CADD 0.32, SIFT 0.03
- V14M (p.Val14Met), rs537605954, gnomAD 7-30921635-G-A, CADD 0.38, SIFT 1.00
- V14A (p.Val14Ala), gnomAD 7-30921636-T-C, CADD 2.60, SIFT 0.01
- V14E (p.Val14Glu), rs1791502261, gnomAD 7-30921636-T-A, CADD 2.13, SIFT 0.00
- V15M (p.Val15Met), rs777773161, ExAC rs777773161, gnomAD rs777773161, REVEL 0.45, MetaLR 0.56, Variant assessed as somatic; moderate impact.
- A16T (p.Ala16Thr), NCI-TCGA TCGA novel, MetaLR 0.90, MetaSVM 1.02, Variant assessed as somatic; moderate impact.
- A16V (p.Ala16Val), gnomAD rs1291941073, REVEL 0.88, MetaLR 0.88, Uncertain significance, not specified
- A16A (p.Ala16Ala), rs747080951, gnomAD 7-30911957-C-G, CADD 7.74
- E17K (p.Glu17Lys), ExAC rs771328144, gnomAD rs771328144, REVEL 0.93, MetaLR 0.98
- E17Q (p.Glu17Gln), ExAC rs771328144, gnomAD rs771328144, MetaLR 0.98, MetaSVM 1.04
- E17G (p.Glu17Gly), gnomAD 7-30911959-A-G, REVEL 0.97, MetaLR 0.97
- F18L (p.Phe18Leu), NCI-TCGA Cosmic COSV6126, Variant assessed as somatic; moderate impact.
- F18V (p.Phe18Val), Ensembl rs1584377278, MetaLR 0.79, MetaSVM 0.71
- F18F (p.Phe18Phe), rs542172945, gnomAD 7-30911963-C-T, CADD 12.90
- F18Y (p.Phe18Tyr), rs1177291310, gnomAD 7-30921663-T-A, CADD 5.46, SIFT 0.00
- L19V (p.Leu19Val), TOPMed rs1476942158, gnomAD rs1476942158, REVEL 0.21, MetaLR 0.39
- A20G (p.Ala20Gly), gnomAD rs1424356551, REVEL 0.35, MetaLR 0.33
- A20T (p.Ala20Thr), TOPMed rs1791175731, gnomAD rs1791175731, REVEL 0.86, MetaLR 0.88
- A20P (p.Ala20Pro), rs776037098, gnomAD 7-30911965-TG-T, CADD 25.60
- A20S (p.Ala20Ser), gnomAD 7-30911967-G-T, REVEL 0.68, MetaLR 0.78
- A20V (p.Ala20Val), gnomAD 7-30921666-C-T, CADD 4.22, SIFT 0.00
- T21M (p.Thr21Met), rs746048942, ClinGen CA4208034, ClinVar RCV004298771, ExAC rs746048942, REVEL 0.36, MetaLR 0.75, Likely benign, not specified
- T21A (p.Thr21Ala), gnomAD 7-30911970-A-G, REVEL 0.73, MetaLR 0.89
- T21T (p.Thr21Thr), rs556771402, gnomAD 7-30911972-G-A, CADD 12.50
- T21I (p.Thr21Ile), rs1276151898, gnomAD 7-30921618-C-T, CADD 1.99, SIFT 0.00
- T22N (p.Thr22Asn), rs1393593188, ClinGen CA367147464, ClinVar RCV001867158, gnomAD rs1393593188, REVEL 0.49, MetaLR 0.73, Uncertain significance, not provided
- T22I (p.Thr22Ile), gnomAD 7-30911974-C-T, REVEL 0.29, MetaLR 0.50
- T22T (p.Thr22Thr), rs1022673944, gnomAD 7-30911975-C-A, CADD 10.40
- L23F (p.Leu23Phe), TOPMed rs1280879987, gnomAD rs1280879987, REVEL 0.37, MetaLR 0.60
- L23V (p.Leu23Val), TOPMed rs1280879987, gnomAD rs1280879987, REVEL 0.36, MetaLR 0.51
- L23L (p.Leu23Leu), gnomAD 7-30911978-C-G, CADD 10.80
- L23R (p.Leu23Arg), rs750771143, gnomAD 7-30921672-T-G, CADD 1.62, SIFT 0.00
- L24del (p.Leu24del), rs2128590552, gnomAD 7-30921673-TCTC-T, CADD 4.25
- L23P (p.Leu23Pro), gnomAD 7-30921678-T-C, CADD 6.37, SIFT 0.00
- F24Y (p.Phe24Tyr), NCI-TCGA TCGA novel, MetaLR 0.88, MetaSVM 0.93, Variant assessed as somatic; moderate impact.
- F24C (p.Phe24Cys), rs749625062, gnomAD 7-30911975-CCT-C, CADD 30.00
- F24L (p.Phe24Leu), gnomAD 7-30911979-T-C, REVEL 0.86, MetaLR 0.71
- F24F (p.Phe24Phe), rs1791176384, gnomAD 7-30911981-T-C, CADD 10.50
- V25A (p.Val25Ala), rs963825730, gnomAD 7-30921684-T-C, CADD 0.27, SIFT 0.01
- V25E (p.Val25Glu), rs963825730, gnomAD 7-30921684-T-A, CADD 0.21, SIFT 0.08
- V25V (p.Val25Val), rs776813614, gnomAD 7-30921685-G-A, CADD 2.10, SIFT 0.01
- F26L (p.Phe26Leu), NCI-TCGA Cosmic COSV6126, ExAC rs775370815, gnomAD rs775370815, Variant assessed as somatic; moderate impact.
- F26S (p.Phe26Ser), NCI-TCGA TCGA novel, MetaLR 0.61, MetaSVM 0.03, Variant assessed as somatic; moderate impact.
- I27V (p.Ile27Val), TOPMed rs1791176510, gnomAD rs1791176510, REVEL 0.24, MetaLR 0.37
- I27L (p.Ile27Leu), gnomAD 7-30911988-A-C, REVEL 0.28, MetaLR 0.39
- S28G (p.Ser28Gly), ExAC rs762860185, gnomAD rs762860185, REVEL 0.56, MetaLR 0.44
- S28S (p.Ser28Ser), rs764092295, gnomAD 7-30911993-C-T, CADD 15.10
- S28T (p.Ser28Thr), gnomAD 7-30921668-T-A, CADD 0.17, SIFT 0.00
- S28Y (p.Ser28Tyr), rs1334004771, gnomAD 7-30921669-C-A, CADD 2.48, SIFT 0.00
- I29V (p.Ile29Val), TOPMed rs1278450967, gnomAD rs1278450967, REVEL 0.50, MetaLR 0.68
- I29I (p.Ile29Ile), rs773770376, gnomAD 7-30911996-C-T, CADD 3.32
- I29M (p.Ile29Met), gnomAD 7-30921697-C-G, CADD 3.10, SIFT 0.00
- G30S (p.Gly30Ser), 1000Genomes rs147526690, ESP rs147526690, ExAC rs147526690, TOPMed rs147526690, REVEL 0.48, MetaLR 0.81, Uncertain significance, not provided
- G30V (p.Gly30Val), gnomAD 7-30911996-CG-C, CADD 32.00
- G30R (p.Gly30Arg), gnomAD 7-30911997-G-C, REVEL 0.74, MetaLR 0.94
- G30D (p.Gly30Asp), gnomAD 7-30911998-G-A, REVEL 0.76, MetaLR 0.91
- G30A (p.Gly30Ala), gnomAD 7-30921596-G-C, CADD 6.37, SIFT 1.00
- G30W (p.Gly30Trp), gnomAD 7-30921601-G-T, CADD 0.30, SIFT 0.00
- G30E (p.Gly30Glu), rs1791501125, gnomAD 7-30921602-G-A, CADD 5.65, SIFT 0.00
- G30G (p.Gly30Gly), rs1444981926, gnomAD 7-30921603-G-A, CADD 4.70
- S31Y (p.Ser31Tyr), ExAC rs766962806, gnomAD rs766962806, REVEL 0.70, MetaLR 0.84
- S31F (p.Ser31Phe), gnomAD 7-30912001-C-T, REVEL 0.67, MetaLR 0.84
- A32D (p.Ala32Asp), ExAC rs750104687, TOPMed rs750104687, gnomAD rs750104687, REVEL 0.94, MetaLR 0.93
- A32S (p.Ala32Ser), TOPMed rs1193745061, gnomAD rs1193745061, REVEL 0.73, MetaLR 0.89
- A32T (p.Ala32Thr), gnomAD 7-30912003-G-A, REVEL 0.76, MetaLR 0.87
- A32V (p.Ala32Val), rs552531843, gnomAD 7-30921714-C-T, CADD 5.93, SIFT 0.00
- A32A (p.Ala32Ala), rs868506968, gnomAD 7-30921715-T-A, CADD 7.84
- L33P (p.Leu33Pro), rs760251239, ExAC rs760251239, TOPMed rs760251239, gnomAD rs760251239, REVEL 0.86, MetaLR 0.76, Variant assessed as somatic; moderate impact.
- L33C (p.Leu33Cys), rs1562580010, gnomAD 7-30921717-GC-G, CADD 1.85
- L33L (p.Leu33Leu), rs1422934664, gnomAD 7-30921724-G-A, CADD 0.05
- L43del (p.Leu43del), rs954915225, gnomAD 7-30921731-GTCT-G, CADD 4.70
- L33W (p.Leu33Trp), rs1791505822, gnomAD 7-30921735-T-G, CADD 4.38, SIFT 0.00
- L33F (p.Leu33Phe), rs1173441383, gnomAD 7-30921736-G-C, CADD 5.47, SIFT 0.01
- G34R (p.Gly34Arg), gnomAD rs1283558986, REVEL 0.78, MetaLR 0.76
- G34E (p.Gly34Glu), rs144480541, gnomAD 7-30921711-G-A, CADD 3.06, SIFT 0.00
- G34A (p.Gly34Ala), gnomAD 7-30921711-G-C, CADD 2.65, SIFT 0.00
- G34G (p.Gly34Gly), rs770421669, gnomAD 7-30921712-G-T, CADD 5.00
- F35Y (p.Phe35Tyr), TOPMed rs1408614489, gnomAD rs1408614489, REVEL 0.27, MetaLR 0.37
- K36E (p.Lys36Glu), Ensembl rs1485138944, REVEL 0.31, MetaLR 0.49
- K36K (p.Lys36Lys), rs1791177703, gnomAD 7-30912017-A-G, CADD 2.02
- Y37C (p.Tyr37Cys), TOPMed rs1218986771, gnomAD rs1218986771, REVEL 0.64, MetaLR 0.76
- Y37H (p.Tyr37His), ESP rs145372510, ExAC rs145372510, gnomAD rs145372510, REVEL 0.54, MetaLR 0.61
- P38L (p.Pro38Leu), rs104894004, ClinGen CA127496, ClinVar RCV000019425, UniProt VAR 013279, REVEL 0.67, MetaLR 0.54, Pathogenic, Colton-null phenotype
- P38Q (p.Pro38Gln), ExAC rs104894004, TOPMed rs104894004, gnomAD rs104894004, REVEL 0.56, MetaLR 0.54, Pathogenic, in Co(A-B-) antigen
- P38S (p.Pro38Ser), Ensembl rs1791177926, REVEL 0.38, MetaLR 0.37
- P38P (p.Pro38Pro), rs565738930, gnomAD 7-30912023-G-A, CADD 2.95
- P12del (p.Pro12del), gnomAD 7-30921638-TCCC-T, CADD 1.29
- P38H (p.Pro38His), rs1018430650, gnomAD 7-30921642-C-A, CADD 3.17, SIFT 0.00
- P38T (p.Pro38Thr), gnomAD 7-30921650-C-A, CADD 2.85, SIFT 0.00
- P38R (p.Pro38Arg), rs1791505290, gnomAD 7-30921720-C-G, CADD 1.45, SIFT 0.01
- V39G (p.Val39Gly), TOPMed rs1433395263, gnomAD rs1433395263, REVEL 0.50, MetaLR 0.59
- V39M (p.Val39Met), Ensembl rs1791178212, REVEL 0.24, MetaLR 0.61
- V39F (p.Val39Phe), rs1464135558, gnomAD 7-30921731-G-T, CADD 2.53, SIFT 0.01
- V39I (p.Val39Ile), rs1464135558, gnomAD 7-30921731-G-A, CADD 3.06, SIFT 0.32
- V39L (p.Val39Leu), rs1464135558, gnomAD 7-30921731-G-C, CADD 2.66, SIFT 0.04
- G40R (p.Gly40Arg), TOPMed rs1370673845, gnomAD rs1370673845, REVEL 0.26, MetaLR 0.47
- G40V (p.Gly40Val), TOPMed rs1402168267, MetaLR 0.35, MetaSVM -0.82
- G40G (p.Gly40Gly), gnomAD 7-30912029-G-A, CADD 9.14
- N41K (p.Asn41Lys), gnomAD rs1473387576, REVEL 0.22, MetaLR 0.57
- N41S (p.Asn41Ser), Ensembl rs1791178555, MetaLR 0.45, MetaSVM -0.55
- N41D (p.Asn41Asp), gnomAD 7-30912030-A-G, REVEL 0.19, MetaLR 0.48
- N42S (p.Asn42Ser), gnomAD rs1158595259, REVEL 0.26, MetaLR 0.51
- N42D (p.Asn42Asp), gnomAD 7-30912033-A-G, REVEL 0.34, MetaLR 0.59
- N42K (p.Asn42Lys), gnomAD 7-30912035-C-A, REVEL 0.40, MetaLR 0.72
- Q43K (p.Gln43Lys), gnomAD 7-30921589-C-A, CADD 0.17, SIFT 0.79
- T44M (p.Thr44Met), ExAC rs756198958, TOPMed rs756198958, gnomAD rs756198958, REVEL 0.48, MetaLR 0.86
- T44A (p.Thr44Ala), gnomAD 7-30912039-A-G, REVEL 0.32, MetaLR 0.66
- T44T (p.Thr44Thr), gnomAD 7-30912041-G-C, CADD 3.60
- A45E (p.Ala45Glu), 1000Genomes rs28362692, ESP rs28362692, ExAC rs28362692, TOPMed rs28362692, REVEL 0.12, MetaLR 0.32, Benign, in Co(A-B+) antigen
- A45T (p.Ala45Thr), Ensembl rs17852043, MetaLR 0.20, MetaSVM -0.90
- A45V (p.Ala45Val), rs28362692, ClinGen CA127494, ClinVar RCV000019424, ClinVar RCV002054449, REVEL 0.17, MetaLR 0.09, Benign, not provided
- A45A (p.Ala45Ala), rs781356338, gnomAD 7-30912044-G-A, CADD 2.72
- V46G (p.Val46Gly), gnomAD 7-30912046-T-G, REVEL 0.23, MetaLR 0.26
- V46V (p.Val46Val), gnomAD 7-30912047-C-G, CADD 4.52
- V46L (p.Val46Leu), gnomAD 7-30921737-G-T, CADD 3.39, SIFT 0.01
- V46I (p.Val46Ile), gnomAD 7-30921737-G-A, CADD 3.96, SIFT 0.01
- Q47H (p.Gln47His), NCI-TCGA Cosmic COSV6126, MetaLR 0.63, MetaSVM 0.20, Variant assessed as somatic; moderate impact.
- Q47R (p.Gln47Arg), rs377506522, ClinGen CA4208050, ClinVar RCV003563304, ESP rs377506522, REVEL 0.76, MetaLR 0.70, Uncertain significance, not provided
- Q47Q (p.Gln47Gln), gnomAD 7-30912050-G-A, CADD 10.40
- Q47P (p.Gln47Pro), rs1397895008, gnomAD 7-30921739-A-AC, CADD 4.38
- D48E (p.Asp48Glu), gnomAD rs1340576534, REVEL 0.68, MetaLR 0.79
- D48G (p.Asp48Gly), gnomAD rs1314294921, REVEL 0.75, MetaLR 0.61
- D48Y (p.Asp48Tyr), gnomAD 7-30912051-G-T, REVEL 0.92, MetaLR 0.87
- N49S (p.Asn49Ser), ExAC rs770124156, TOPMed rs770124156, gnomAD rs770124156, REVEL 0.35, MetaLR 0.38, Likely benign, not provided
- N49D (p.Asn49Asp), gnomAD 7-30912054-A-G, REVEL 0.47, MetaLR 0.49
- N49H (p.Asn49His), gnomAD 7-30912054-A-C, REVEL 0.52, MetaLR 0.52
- N49N (p.Asn49Asn), rs779776693, gnomAD 7-30912056-C-T, CADD 7.76
- V50M (p.Val50Met), rs200496523, ClinGen CA4208053, ClinVar RCV004212929, 1000Genomes rs200496523, REVEL 0.75, MetaLR 0.89, Uncertain significance, not specified
- V50E (p.Val50Glu), gnomAD 7-30912058-T-A, REVEL 0.95, MetaLR 0.88
- V50V (p.Val50Val), gnomAD 7-30912059-G-A, CADD 11.20
- K51E (p.Lys51Glu), gnomAD 7-30912060-A-G, REVEL 0.77, MetaLR 0.62
- K51R (p.Lys51Arg), rs1791506756, gnomAD 7-30921777-A-G, CADD 1.38, SIFT 0.03
- K51K (p.Lys51Lys), gnomAD 7-30921778-G-A, CADD 0.23
- V52L (p.Val52Leu), 1000Genomes rs35115273, ESP rs35115273, ExAC rs35115273, TOPMed rs35115273, REVEL 0.84, MetaLR 0.80
Public AQP1 analysis runs
- AQP1 analysis run — AQP1 (634 variants) — completed 2026-08-19